Show simple item record

dc.contributor.authorBasu, B
dc.contributor.authorDean, Emma J
dc.contributor.authorPuglisi, M
dc.contributor.authorGreystoke, Alastair
dc.contributor.authorOng, M
dc.contributor.authorBurke, W
dc.contributor.authorCavallin, M
dc.contributor.authorBigley, G
dc.contributor.authorWomack, C
dc.contributor.authorHarrington, E
dc.contributor.authorGreen, S
dc.contributor.authorOelmann, E
dc.contributor.authorde Bono, J
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorBanerji, U
dc.date.accessioned2015-04-16T15:13:52Zen
dc.date.available2015-04-16T15:13:52Zen
dc.date.issued2015-03-24en
dc.identifier.citationFirst-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014. 2015: Clin Cancer Resen
dc.identifier.issn1078-0432en
dc.identifier.pmid25805799en
dc.identifier.doi10.1158/1078-0432.CCR-14-2422en
dc.identifier.urihttp://hdl.handle.net/10541/550235en
dc.description.abstractAZD2014 is a novel, oral, m-TORC 1/2 inhibitor which has shown in-vitro and in-vivo efficacy across a range of preclinical human cancer models.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Researchen
dc.titleFirst-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014.en
dc.typeArticleen
dc.contributor.departmentDrug Development Unit, The Institute of Cancer Research & The Royal Marsdenen
dc.identifier.journalClinical Cancer Researchen
html.description.abstractAZD2014 is a novel, oral, m-TORC 1/2 inhibitor which has shown in-vitro and in-vivo efficacy across a range of preclinical human cancer models.


This item appears in the following Collection(s)

Show simple item record